sitagliptin glp 1 agonist GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? GLP-1: Actions on Beta-cell Mass

Review article: GLP 1 receptor agonists and Glucagon/ GIP / GLP 1 receptor dual or triple Agonistsmechanism of action and emerging therapeutic landscape in MASLD

These insights provide a framework for precision medicine, where genetic profiling may help refine risk stratification and guide targeted therapeutic strategies

For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs

[DOI] [PubMed] [Google Scholar] 349.Elias C.F., Kelly J.F., Lee C.E., Ahima R.S., Drucker D.J., Saper C.B

Most side effects of GLP- 1 and GLP- 1/GIP receptor agonists are mild to moderate and resolve over time

Key takeaways Obesity is a rising epidemic: Obesity and its comorbid conditions are increasingly common and increasingly expensive, with the National Institutes of Health predicting that nearly 50% of U.S